세계의 소아 황반변성 치료 시장 보고서(2025년)
Juvenile Macular Degeneration Treatment Global Market Report 2025
상품코드 : 1751032
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,487,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,376,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,266,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

소아 황반변성 치료 시장 규모는 향후 수년간 강력한 성장이 전망될 예정입니다. 줄기의 중점화, 임상시험 건수 증가, 유전자 치료에 대한 투자 확대 등의 요인에 의한 것으로 예측됩니다.

망막장애의 유병률 증가는 향후 몇 년간의 소아 황반변성 치료 시장의 확대를 견인할 것으로 예측됩니다. 당뇨병 망막증과 같은 질병이 증가함에 따라 더욱 흔해지고 있습니다. Retina Australia의 2024년 11월 보고서에 따르면 호주는 약 1만 9,000명, 즉 1,380명 중 1명이 유전성 망막 질환(IRD)을 앓고 있다고 추정되고 있습니다. 성병(AMD)을 앓고 있는 미국인의 수는 2030년까지 210만명에서 370만명으로 증가할 것으로 예측했습니다.

소아 황반변성 치료 시장의 기업은 유전자 치료의 전달과 치료 성적을 개선하기 위해 듀얼 AAV(아데노 관련 바이러스) 벡터와 같은 최첨단 유전자 치료에 주력하고 있습니다. 이중 AAV 벡터는 두 개의 AAV 벡터를 사용하여 단일 AAV 용량을 초과하는 큰 치료 유전자를 전달하여 유전자 치료를 더욱 효과적으로 만듭니다. 공학 기업 SpliceBio는 SB-007의 1/2 상 ASTRA 시험에서 첫 번째 환자 투여를 발표했습니다. 이 이중 AAV 벡터 유전자 치료법은 전신 ABCA4 단백질 발현을 회복하는 것을 목적으로 한 것으로, 현재 치료법이 승인되지 않은 젊은 성 황반변성의 일종인 스타가르트병의 치료법이 될 가능성이 있습니다. 이 획기적인 치료법은 희귀한 망막 질환의 치료에 있어서의 큰 진보입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

SHW
영문 목차

영문목차

Juvenile macular degeneration (Stargardt disease) treatment involves various approaches aimed at managing vision loss and enhancing the quality of life for individuals affected by this genetic eye condition. It is caused by genetic mutations that damage the macula, the central part of the retina, leading to gradual vision deterioration and difficulties with tasks such as reading and facial recognition.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary types of juvenile macular degeneration treatment are wet age-related macular degeneration and dry age-related macular degeneration. Wet age-related macular degeneration refers to a condition in which abnormal blood vessels form beneath the retina, causing fluid or blood leakage and rapid central vision loss. Treatments for juvenile macular degeneration include devices, medications, and surgery. These treatments focus on vision preservation, disease management, symptom relief, preventive care, and participation in clinical trials. They are provided through various channels such as hospitals, ambulatory surgical centers, and other healthcare settings.

The juvenile macular degeneration treatment market research report is one of a series of new reports from The Business Research Company that provides juvenile macular degeneration treatment market statistics, including the juvenile macular degeneration treatment industry global market size, regional shares, competitors with the juvenile macular degeneration treatment market share, detailed juvenile macular degeneration treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the juvenile macular degeneration treatment industry. These juvenile macular degeneration treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The juvenile macular degeneration treatment market size has grown strongly in recent years. It will grow from$1.28 billion in 2024 to $1.39 billion in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth during the historic period can be attributed to several factors, including the rising prevalence of genetic eye disorders, increased investment in ophthalmic research, a growing focus on pediatric eye care, the increasing prevalence of vision impairment among children, and the expanding integration of artificial intelligence in eye care diagnostics.

The juvenile macular degeneration treatment market size is expected to see strong growth in the next few years. It will grow to$1.88 billion in 2029 at a compound annual growth rate (CAGR) of 8.0%. The growth during the forecast period can be attributed to factors such as the growing geriatric population, an increase in ophthalmic biotechnology startups, a stronger focus on targeted drug delivery systems, a rise in the number of clinical trials, and greater investment in gene therapy. Key trends during this period include advancements in genetic testing, the development of gene therapies, progress in stem cell research, regulatory support for innovative treatments, and the adoption of personalized medicine approaches.

The growing prevalence of retinal disorders is expected to drive the expansion of the juvenile macular degeneration treatment market in the coming years. Retinal disorders, which affect the light-sensitive layer of the eye and lead to vision impairment or loss, are becoming more prevalent, particularly due to the rise in diabetes and conditions such as diabetic retinopathy, which gradually damages the retina. Juvenile macular degeneration treatments are essential in managing these retinal conditions by preserving vision through early intervention, particularly for young patients. For example, a November 2024 report from Retina Australia estimates that approximately 19,000 individuals in Australia, or 1 in 1,380 people, live with inherited retinal diseases (IRDs). Additionally, the National Eye Institute predicts that the number of Americans with advanced age-related macular degeneration (AMD) will grow from 2.1 million to 3.7 million by 2030. These statistics underline the increasing need for juvenile macular degeneration treatments, driving market growth.

Companies in the juvenile macular degeneration treatment market are focusing on cutting-edge gene therapies, such as dual adeno-associated viral (AAV) vectors, to improve gene therapy delivery and treatment outcomes. Dual AAV vectors utilize two AAV vectors to deliver large therapeutic genes that exceed the capacity of a single AAV, making gene therapy more effective. For instance, in March 2025, SpliceBio, a Spain-based biotechnology company, announced the first patient dosing in its Phase 1/2 ASTRA study for SB-007. This dual AAV vector gene therapy aims to restore full-length ABCA4 protein expression and could offer a potential treatment for Stargardt disease, a form of juvenile macular degeneration that currently has no approved treatments. This breakthrough represents a significant advancement in treating rare retinal diseases.

In July 2023, Astellas Pharma Inc., a Japan-based pharmaceutical company, acquired IVERIC Bio Inc., a US-based company specializing in juvenile macular degeneration treatments, particularly for Stargardt disease. Through this acquisition, Astellas aims to enhance its ophthalmology portfolio, accelerate the development of innovative treatments for retinal diseases, and expand its expertise in gene therapy and complement inhibition. This acquisition strengthens Astellas' position in the juvenile macular degeneration treatment market, positioning it to offer novel solutions for conditions such as Stargardt disease and geographic atrophy.

Major players in the juvenile macular degeneration treatment market are F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, AbbVie Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen Inc., Santen Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Samsung Bioepis Co. Ltd., Spark Therapeutics Inc., Polpharma Biologics S.A., OrCam Technologies Ltd., Alkeus Pharmaceuticals Inc., Bioeq AG, NuEyes Technologies Inc., Coherus BioSciences Inc., eSight Eyewear Inc., MeiraGTx Holdings plc, and Kubota Pharmaceutical Holdings Co. Ltd.

North America was the largest region in the juvenile macular degeneration treatment market in 2024. The regions covered in juvenile macular degeneration treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the juvenile macular degeneration treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The juvenile macular degeneration treatment market consists of revenues earned by entities by providing services such as vision therapy, low vision rehabilitation, genetic counseling, nutritional counseling, and psychological support for vision loss management. The market value includes the value of related goods sold by the service provider or included within the service offering. The juvenile macular degeneration (JMD) treatment market also includes sales of prescription eyewear, low vision aids, braille displays, specialty lighting devices, and dietary supplements for eye health. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Juvenile Macular Degeneration Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on juvenile macular degeneration treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for juvenile macular degeneration treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The juvenile macular degeneration treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Juvenile Macular Degeneration Treatment Market Characteristics

3. Juvenile Macular Degeneration Treatment Market Trends And Strategies

4. Juvenile Macular Degeneration Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Juvenile Macular Degeneration Treatment Growth Analysis And Strategic Analysis Framework

6. Juvenile Macular Degeneration Treatment Market Segmentation

7. Juvenile Macular Degeneration Treatment Market Regional And Country Analysis

8. Asia-Pacific Juvenile Macular Degeneration Treatment Market

9. China Juvenile Macular Degeneration Treatment Market

10. India Juvenile Macular Degeneration Treatment Market

11. Japan Juvenile Macular Degeneration Treatment Market

12. Australia Juvenile Macular Degeneration Treatment Market

13. Indonesia Juvenile Macular Degeneration Treatment Market

14. South Korea Juvenile Macular Degeneration Treatment Market

15. Western Europe Juvenile Macular Degeneration Treatment Market

16. UK Juvenile Macular Degeneration Treatment Market

17. Germany Juvenile Macular Degeneration Treatment Market

18. France Juvenile Macular Degeneration Treatment Market

19. Italy Juvenile Macular Degeneration Treatment Market

20. Spain Juvenile Macular Degeneration Treatment Market

21. Eastern Europe Juvenile Macular Degeneration Treatment Market

22. Russia Juvenile Macular Degeneration Treatment Market

23. North America Juvenile Macular Degeneration Treatment Market

24. USA Juvenile Macular Degeneration Treatment Market

25. Canada Juvenile Macular Degeneration Treatment Market

26. South America Juvenile Macular Degeneration Treatment Market

27. Brazil Juvenile Macular Degeneration Treatment Market

28. Middle East Juvenile Macular Degeneration Treatment Market

29. Africa Juvenile Macular Degeneration Treatment Market

30. Juvenile Macular Degeneration Treatment Market Competitive Landscape And Company Profiles

31. Juvenile Macular Degeneration Treatment Market Other Major And Innovative Companies

32. Global Juvenile Macular Degeneration Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Juvenile Macular Degeneration Treatment Market

34. Recent Developments In The Juvenile Macular Degeneration Treatment Market

35. Juvenile Macular Degeneration Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기